|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 1. Mineral metabolism parameters, clinical symptoms and treatment during follow-up** | | | | | | |
| **Date Follow up** | **June 2022** | **July 2022** | **October 2022** | **April 2023** | **July 2023** | **April 2024** |
| PTH, pg/ml | 47 | 55 | 111 | 98 | 600 | 345 |
| AP, UI/L | 65 | 81 | 85 | 159 | 159 | 174 |
| Ca, mg/dL | 8.1 | 9.2 | 9.4 | 9.6 | 8.3 | 9.4 |
| P, mg/dL | 8.6 | 9.7 | 8.5 | 5 | 4.8 | 4.7 |
| Ferritin, ng/mL | 640 |  | 381 |  | 570 | 425 |
| Chelator of P | Calcium acetate | Sevelamer | Sevelamer | Sevelamer | Sevelamer | Sevelamer |
| STS | No | Yes | Yes | No | No | No |
| RRT | DPAC | HD | HD | HD | HD | HD |
| QT, hours |  | 5 | 5 | 4 | 4 | 4 |
| EC | Yes | Yes | No | No | No | No |
| Cinacalcet |  |  |  |  |  | Yes |
| PTH: parathormone, AP: alkaline phosphatase, Ca: calcium, P: phosphorus, STS: sodium thiosulphate, RRT: renal replacement therapy, QT: dialysis time, EC: extraosseous calcifications, DPAC: continuous ambulatory peritoneal dialysis, HD: hemodialysis | | | | | | |
|  |  |  |  |  |  |  |